Unknown

Dataset Information

0

Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.

ABSTRACT: HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400?mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.

SUBMITTER: Cressey TR 

PROVIDER: S-EPMC5106325 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.

Cressey Tim R TR   Hazra Rohan R   Wiznia Andrew A   Foca Marc M   Jean-Philippe Patrick P   Graham Bobbie B   King Jennifer R JR   Britto Paula P   Carey Vincent J VJ   Acosta Edward P EP   Yogev Ram R  

The Pediatric infectious disease journal 20161201 12

HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population. ...[more]

Similar Datasets

Unknown Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.
| S-EPMC3244641 | biostudies-other
Unknown Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients.
| S-EPMC4312629 | biostudies-literature
Unknown Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics.
| S-EPMC3912854 | biostudies-literature
Unknown Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
| S-EPMC5407125 | biostudies-literature
Unknown Outcomes of Integrase Inhibitor-based Antiretroviral Therapy in a Clinical Cohort of Treatment-experienced Children, Adolescents and Young Adults With HIV Infection.
| S-EPMC8075057 | biostudies-literature
Unknown No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.
| S-EPMC6147473 | biostudies-literature
Unknown Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults.
| S-EPMC3490699 | biostudies-literature
Unknown Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children.
| S-EPMC3165353 | biostudies-literature
Unknown Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093.
| S-EPMC4604048 | biostudies-literature
Unknown HIV preexposure prophylaxis for adolescents and young adults.
| S-EPMC5762125 | biostudies-other